Intestinal flora regulates tumor microenvironment components. TAMs: Helicobacter hepaticus can activate TAMs and inhibit the production of IL-10, thus inhibiting the development of breast cancer. The imbalance of gut microbiota directly activates macrophages, macrophages release IL-6, TNF-α and CXCL10. IL-6 and TNF-α accelerate the development of CRC by promoting EMT, while CXCL10 induces T-cell infiltration in the tumor microenvironment and promotes the development of HCC. Intestinal microbiota bacterial diseases induce tumor cells to secrete CTSK, thereby activating macrophages through mTOR-dependent pathways. CTSK stimulates the macrophage secretion of IL-10 and IL-17, thus promoting the invasion and metastasis of CRC cells. Some symbiotic microbiota stimulate macrophages to increase c-Jun phosphorylation in CRC cells through the JNK signaling pathway, thus accelerating CRC cell proliferation. Intestinal microbiota bacterial diseases also induce the production of IL-25 from cluster cells, which promotes EMT and the migration of HCC cells. CAFs: CAFs influence the tumor immune microenvironment by recruiting chemokines and immune factors. MDSCs: IL-17 recruits bone MDSCs into the colon tumor microenvironment of mice colonized with enterotoxin bacteria, which indirectly induce the ectopic production of chemokines and growth factors through direct interaction with IL-17 receptors in CECs, and the expression of IL-17 in submucosa. IL-17 and transformed CECs jointly promote tumor development with angiogenic mediators, namely MMP-9 and VEGF, by inhibiting immune effector cells and activating the STAT3 signaling pathway. Early lack of microbiota in mice enhances the expression of C-X-C motif receptor 2 ligands. A number of gut pathogenic microorganisms or gut microbiota and their synergistic interactions with cytokines activate and proliferate MDSCs in the tumor microenvironment, thus mediating the immune escape of tumor cells. TANs: Helicobacter hepaticus can induce the generation of neutrophils, thereby inducing nitric oxide and TNF-α increased content, which activates the NF-κB signaling pathway and promotes tumor generation. DCs: Lipopolysaccharide and TNF-α stimulate DCs to mature and activate, and subsequently activate T cells to produce IL-2 to form an antitumor microenvironment. TAMs, tumor-associated macrophages; CRC, colorectal cancer; EMT, epithelial-mesenchymal transition; HCC, hepatocellular carcinoma; CTSK, carnosine K; CAFs, cancer-associated fibroblasts; MDSCs, myeloid-derived suppressor cells; CECs, colon epithelial cells; DCs, dendritic cells; TANs, tumor-associated neutrophils; CXCL, C-X-C motif ligand